- : Identification and construction of combinatory cancer hallmark–based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer (Opens in a new window)Get@NRC
|DOI||Resolve DOI: http://doi.org/10.1001/jamaoncol.2015.3413|
|Author||Search for: Gao, Shanwu; Search for: Tibiche, Chabane; Search for: Zou, Jinfeng; Search for: Zaman, Naif; Search for: Trifiro, Mark; Search for: O’Connor-McCourt, Maureen; Search for: Wang, Edwin|
|Journal title||JAMA Oncology|
|Abstract||IMPORTANCE Decisions regarding adjuvant therapy in patients with stage II colorectal cancer (CRC) have been among the most challenging and controversial in oncology over the past 20 years.
OBJECTIVE To develop robust combinatory cancer hallmark–based gene signature sets (CSS sets) that more accurately predict prognosis and identify a subset of patients with stage II CRC who could gain survival benefits from adjuvant chemotherapy.
DESIGN, SETTING, AND PARTICIPANTS Thirteen retrospective studies of patients with stage II CRC who had clinical follow-up and adjuvant chemotherapy were analyzed. Respective totals of 162 and 843 patients from 2 and 11 independent cohorts were used as the discovery and validation cohorts, respectively. A total of 1005 patients with stage II CRC were included in the 13 cohorts. Among them, 84 of 416 patients in 3 independent cohorts received fluorouracil-based adjuvant chemotherapy.
MAIN OUTCOMES AND MEASURES Identification of CSS sets to predict relapse-free survival and identify a subset of patients with stage II CRC who could gain substantial survival benefits from fluorouracil-based adjuvant chemotherapy.
RESULTS Eight cancer hallmark–based gene signatures (30 genes each) were identified and used to construct CSS sets for determining prognosis. The CSS sets were validated in 11 independent cohorts of 767 patients with stage II CRC who did not receive adjuvant chemotherapy. The CSS sets accurately stratified patients into low-, intermediate-, and high-risk groups. Five-year relapse-free survival rates were 94%, 78%, and 45%, respectively, representing 60%, 28%, and 12% of patients with stage II disease. The 416 patients with CSS set–defined high-risk stage II CRC who received fluorouracil-based adjuvant chemotherapy showed a substantial gain in survival benefits from the treatment (ie, recurrence reduced by 30%-40% in 5 years).
Conclusions and Relevance The CSS sets substantially outperformed other prognostic predictors of stage 2 CRC. They are more accurate and robust for prognostic predictions and facilitate the identification of patients with stage II disease who could gain survival benefit from fluorouracil-based adjuvant chemotherapy.|
|Publisher||American Medical Association|
|Affiliation||Human Health Therapeutics; National Research Council Canada|
|Export citation||Export as RIS|
|Report a correction||Report a correction|
|Bookmark and share|